KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Accumulated Expenses (2016 - 2025)

TherapeuticsMD filings provide 16 years of Other Accumulated Expenses readings, the most recent being $301000.0 for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $301000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $301000.0, a N/A change, with the full-year FY2024 number at $88000.0, down 78.48% from a year prior.
  • Other Accumulated Expenses hit $301000.0 in Q3 2025 for TherapeuticsMD, up from $202000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $59.2 million in Q2 2022 to a low of $88000.0 in Q4 2024.
  • Median Other Accumulated Expenses over the past 5 years was $11.5 million (2023), compared with a mean of $16.2 million.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 580.86% in 2021 and later plummeted 97.83% in 2023.
  • TherapeuticsMD's Other Accumulated Expenses stood at $13.3 million in 2021, then soared by 41.3% to $18.8 million in 2022, then plummeted by 97.83% to $409000.0 in 2023, then plummeted by 78.48% to $88000.0 in 2024, then soared by 242.05% to $301000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $301000.0 (Q3 2025), $202000.0 (Q2 2025), and $249000.0 (Q1 2025) per Business Quant data.